/ Credibility Index / Revance Daxxify Provider Network

Revance Daxxify Provider Network

Manufacturer Network · Daxxify neurotoxin provider network
C+

Mixed (C+) — Aesthetic Credibility Grade

Revance Therapeutics manufactures Daxxify (newer neurotoxin alternative to Botox) launched 2022. RVNC NASDAQ-public. Provider network is still being established; clinical-result longevity claims are subject to ongoing review by FDA and academic literature.

66
Composite / 100
/ Subscore Breakdown · 5 Dimensions

Where this grade comes from.

Practitioner Credentialing
C+
Injury / Complication Rate
C+
Regulatory Track Record
B-
Pricing Transparency
C+
Aftercare Quality
C+
/ Public-Record Events

Key events & disclosures.

  • RVNC NASDAQ public
  • Daxxify launched 2022
  • Longer-duration neurotoxin claim under review
  • Newer provider network

/ Best for

Customers receiving Daxxify through board-certified providers familiar with the product (still relatively new market).

/ Watch out for

Newer product means less long-term safety data than Botox. Verify provider's specific experience with Daxxify.